Global Primary Myelofibrosis Drug market size is predicted to grow from US$ 164 million in 2025 to US$ 290 million in 2031; it is expected to grow at a CAGR of 10.0% from 2025 to 2031. Get Access Now!

Global Primary Myelofibrosis Drug Market Growth Status and Outlook 2025-2031

The global Primary Myelofibrosis Drug market size is predicted to grow from US$ 164 million in 2025 to US$ 290 million in 2031; it is expected to grow at a CAGR of 10.0% from 2025 to 2031. Primary myelofibrosis (MF) is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. Researchers believe MF may be caused by abnormal blood stem cells in the bone marrow. The abnormal stem cells produce mature cells that grow quickly and take over the bone marrow, causing both fibrosis (scar tissue formation) and chronic inflammation. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Primary Myelofibrosis Drug Industry Forecast looks at past sales and reviews total world Primary Myelofibrosis Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Primary Myelofibrosis Drug sales for 2025 through 2031. With Primary Myelofibrosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Myelofibrosis Drug industry. This Insight Report provides a comprehensive analysis of the global Primary Myelofibrosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Primary Myelofibrosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Primary Myelofibrosis Drug market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Myelofibrosis Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Myelofibrosis Drug. This report presents a comprehensive overview, market shares, and growth opportunities of Primary Myelofibrosis Drug market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; JAK 1 &nbsp;&nbsp;&nbsp; JAK 2 &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Adults &nbsp;&nbsp;&nbsp; Children This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; GSK &nbsp;&nbsp;&nbsp; AbbVie &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Celgene &nbsp;&nbsp;&nbsp; Grunenthal &nbsp;&nbsp;&nbsp; Incyte &nbsp;&nbsp;&nbsp; CTI BioPharma &nbsp;&nbsp;&nbsp; Bristol Myers Squibb &nbsp;&nbsp;&nbsp; Suzhou Zelgen Biopharmaceuticals Key Questions Addressed in this Report What is the 10-year outlook for the global Primary Myelofibrosis Drug market? What factors are driving Primary Myelofibrosis Drug market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Primary Myelofibrosis Drug market opportunities vary by end market size? How does Primary Myelofibrosis Drug break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Primary Myelofibrosis Drug Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Primary Myelofibrosis Drug by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Primary Myelofibrosis Drug by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Primary Myelofibrosis Drug Segment by Type &nbsp;2.2.1 JAK 1 &nbsp;2.2.2 JAK 2 &nbsp;2.2.3 Others &nbsp;2.3 Primary Myelofibrosis Drug Sales by Type &nbsp;2.3.1 Global Primary Myelofibrosis Drug Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Primary Myelofibrosis Drug Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Primary Myelofibrosis Drug Sale Price by Type (2020-2025) &nbsp;2.4 Primary Myelofibrosis Drug Segment by Application &nbsp;2.4.1 Adults &nbsp;2.4.2 Children &nbsp;2.5 Primary Myelofibrosis Drug Sales by Application &nbsp;2.5.1 Global Primary Myelofibrosis Drug Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Primary Myelofibrosis Drug Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Primary Myelofibrosis Drug Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Primary Myelofibrosis Drug Breakdown Data by Company &nbsp;3.1.1 Global Primary Myelofibrosis Drug Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Primary Myelofibrosis Drug Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Primary Myelofibrosis Drug Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Primary Myelofibrosis Drug Revenue by Company (2020-2025) &nbsp;3.2.2 Global Primary Myelofibrosis Drug Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Primary Myelofibrosis Drug Sale Price by Company &nbsp;3.4 Key Manufacturers Primary Myelofibrosis Drug Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Primary Myelofibrosis Drug Product Location Distribution &nbsp;3.4.2 Players Primary Myelofibrosis Drug Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Primary Myelofibrosis Drug by Geographic Region &nbsp;4.1 World Historic Primary Myelofibrosis Drug Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Primary Myelofibrosis Drug Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Primary Myelofibrosis Drug Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Primary Myelofibrosis Drug Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Primary Myelofibrosis Drug Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Primary Myelofibrosis Drug Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Primary Myelofibrosis Drug Sales Growth &nbsp;4.4 APAC Primary Myelofibrosis Drug Sales Growth &nbsp;4.5 Europe Primary Myelofibrosis Drug Sales Growth &nbsp;4.6 Middle East & Africa Primary Myelofibrosis Drug Sales Growth 5 Americas &nbsp;5.1 Americas Primary Myelofibrosis Drug Sales by Country &nbsp;5.1.1 Americas Primary Myelofibrosis Drug Sales by Country (2020-2025) &nbsp;5.1.2 Americas Primary Myelofibrosis Drug Revenue by Country (2020-2025) &nbsp;5.2 Americas Primary Myelofibrosis Drug Sales by Type (2020-2025) &nbsp;5.3 Americas Primary Myelofibrosis Drug Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Primary Myelofibrosis Drug Sales by Region &nbsp;6.1.1 APAC Primary Myelofibrosis Drug Sales by Region (2020-2025) &nbsp;6.1.2 APAC Primary Myelofibrosis Drug Revenue by Region (2020-2025) &nbsp;6.2 APAC Primary Myelofibrosis Drug Sales by Type (2020-2025) &nbsp;6.3 APAC Primary Myelofibrosis Drug Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Primary Myelofibrosis Drug by Country &nbsp;7.1.1 Europe Primary Myelofibrosis Drug Sales by Country (2020-2025) &nbsp;7.1.2 Europe Primary Myelofibrosis Drug Revenue by Country (2020-2025) &nbsp;7.2 Europe Primary Myelofibrosis Drug Sales by Type (2020-2025) &nbsp;7.3 Europe Primary Myelofibrosis Drug Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Primary Myelofibrosis Drug by Country &nbsp;8.1.1 Middle East & Africa Primary Myelofibrosis Drug Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Primary Myelofibrosis Drug Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Primary Myelofibrosis Drug Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Primary Myelofibrosis Drug Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Primary Myelofibrosis Drug &nbsp;10.3 Manufacturing Process Analysis of Primary Myelofibrosis Drug &nbsp;10.4 Industry Chain Structure of Primary Myelofibrosis Drug 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Primary Myelofibrosis Drug Distributors &nbsp;11.3 Primary Myelofibrosis Drug Customer 12 World Forecast Review for Primary Myelofibrosis Drug by Geographic Region &nbsp;12.1 Global Primary Myelofibrosis Drug Market Size Forecast by Region &nbsp;12.1.1 Global Primary Myelofibrosis Drug Forecast by Region (2026-2031) &nbsp;12.1.2 Global Primary Myelofibrosis Drug Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Primary Myelofibrosis Drug Forecast by Type (2026-2031) &nbsp;12.7 Global Primary Myelofibrosis Drug Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 GSK &nbsp;13.1.1 GSK Company Information &nbsp;13.1.2 GSK Primary Myelofibrosis Drug Product Portfolios and Specifications &nbsp;13.1.3 GSK Primary Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 GSK Main Business Overview &nbsp;13.1.5 GSK Latest Developments &nbsp;13.2 AbbVie &nbsp;13.2.1 AbbVie Company Information &nbsp;13.2.2 AbbVie Primary Myelofibrosis Drug Product Portfolios and Specifications &nbsp;13.2.3 AbbVie Primary Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 AbbVie Main Business Overview &nbsp;13.2.5 AbbVie Latest Developments &nbsp;13.3 Novartis &nbsp;13.3.1 Novartis Company Information &nbsp;13.3.2 Novartis Primary Myelofibrosis Drug Product Portfolios and Specifications &nbsp;13.3.3 Novartis Primary Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Novartis Main Business Overview &nbsp;13.3.5 Novartis Latest Developments &nbsp;13.4 Celgene &nbsp;13.4.1 Celgene Company Information &nbsp;13.4.2 Celgene Primary Myelofibrosis Drug Product Portfolios and Specifications &nbsp;13.4.3 Celgene Primary Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Celgene Main Business Overview &nbsp;13.4.5 Celgene Latest Developments &nbsp;13.5 Grunenthal &nbsp;13.5.1 Grunenthal Company Information &nbsp;13.5.2 Grunenthal Primary Myelofibrosis Drug Product Portfolios and Specifications &nbsp;13.5.3 Grunenthal Primary Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Grunenthal Main Business Overview &nbsp;13.5.5 Grunenthal Latest Developments &nbsp;13.6 Incyte &nbsp;13.6.1 Incyte Company Information &nbsp;13.6.2 Incyte Primary Myelofibrosis Drug Product Portfolios and Specifications &nbsp;13.6.3 Incyte Primary Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Incyte Main Business Overview &nbsp;13.6.5 Incyte Latest Developments &nbsp;13.7 CTI BioPharma &nbsp;13.7.1 CTI BioPharma Company Information &nbsp;13.7.2 CTI BioPharma Primary Myelofibrosis Drug Product Portfolios and Specifications &nbsp;13.7.3 CTI BioPharma Primary Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 CTI BioPharma Main Business Overview &nbsp;13.7.5 CTI BioPharma Latest Developments &nbsp;13.8 Bristol Myers Squibb &nbsp;13.8.1 Bristol Myers Squibb Company Information &nbsp;13.8.2 Bristol Myers Squibb Primary Myelofibrosis Drug Product Portfolios and Specifications &nbsp;13.8.3 Bristol Myers Squibb Primary Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Bristol Myers Squibb Main Business Overview &nbsp;13.8.5 Bristol Myers Squibb Latest Developments &nbsp;13.9 Suzhou Zelgen Biopharmaceuticals &nbsp;13.9.1 Suzhou Zelgen Biopharmaceuticals Company Information &nbsp;13.9.2 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product Portfolios and Specifications &nbsp;13.9.3 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Suzhou Zelgen Biopharmaceuticals Main Business Overview &nbsp;13.9.5 Suzhou Zelgen Biopharmaceuticals Latest Developments 14 Research Findings and Conclusion

Report	Global Primary Myelofibrosis Drug Market Growth 2025-2031
Selected License	Multi ID: LPI35902

Buyer Information

Order Summary